Martin K. (Casey) Childers Do, PhD
About Martin K. (Casey) Childers Do, PhD
Martin K. (Casey) Childers, DO, PhD, serves as the Chief Medical Officer at Asklepios BioPharmaceutical, Inc. He has extensive experience in clinical development, regulatory strategy, and gene therapies, with a strong academic background in medicine and pharmacology.
Current Role at Asklepios BioPharmaceutical
Martin K. (Casey) Childers serves as the Chief Medical Officer at Asklepios BioPharmaceutical, Inc. (AskBio) since 2017. In this role, he oversees the clinical development and regulatory strategies for the company's gene therapy programs. His responsibilities include leading initiatives related to AAV gene transfer, particularly for neuromuscular and orphan diseases. Childers plays a critical role in advancing the company's clinical pipeline and ensuring compliance with regulatory standards.
Education and Expertise
Childers has an extensive educational background in medicine and science. He earned a Doctor of Osteopathic Medicine from Western University of Health Sciences from 1986 to 1990. He furthered his studies at the University of Missouri-Columbia, where he completed a PhD in Pharmacology and Physiology between 1997 and 2001. Additionally, he completed a residency in Physical Medicine and Rehabilitation at the same institution from 1991 to 1994, achieving Diplomate status from the American Academy of Physical Medicine and Rehabilitation (AAPM&R). He also holds a Bachelor of Arts in Music from Seattle Pacific University, obtained from 1977 to 1980.
Professional Experience
Before joining Asklepios BioPharmaceutical, Childers held a position as a Professor at the University of Washington from 2012 to 2018. His professional experience includes conducting diligence assessments for new assets under investigation for acquisition and partnership in clinical programs. He has a deep understanding of designing pre-clinical studies that support AAV gene therapies and has led translational and clinical development efforts in this area.
Regulatory Strategy and Clinical Trials
Childers has significant expertise in executing regulatory strategies and preparing Investigational New Drug (IND) applications for phase 1 and 2 clinical trial launches. His experience includes presenting key clinical and pipeline information to various stakeholders, including advisory boards, key opinion leaders (KOLs), the FDA, and investors. This involvement underscores his role in facilitating communication between the company and regulatory bodies, ensuring that clinical programs align with industry standards.